期刊文献+

BPH相关LUTS与各临床影响因素关系的研究 被引量:5

Relationship between lower urinary tract symptoms and clinical factors in patients with benign prostatic hyperplasia
原文传递
导出
摘要 目的 研究前列腺增生症(BPH)相关下尿路症状(LUTS)与各临床影响因素的关系.方法 选择本院收治的146例BPH患者为研究对象,采用回顾性调查法分别调查本组患者的病历资料,包括年龄、病程、前列腺体积、前列腺特异抗原(PSA)、前列腺增生家族史、情绪、血清雌激素等.以患者下尿路症状严重程度为因变量,以可能导致患者下尿路症状加重的各类因素为自变量,先进行单因素分析,单因素分析后再运用Logistic回归分析工具进行多因素分析.结果 单因素分析结果显示,年龄、最大尿流量、PSA、HAMD评分及血清雌激素均是影响BPH相关LUTS严重程度的重要因素(P<0.05);Logistic多因素回归分析结果显示,年龄、最大尿流量、PSA及血清雌激素是影响BPH相关LUTS严重程度的独立危险因素(P<0.05).结论 年龄增长、最大尿流量<5mL/s、PSA升高及血清雌激素升高均是加重前列腺增生症相关下尿路症状严重程度的重要危险因素. Objectives To study the relationship between lower urinary tract symptoms (LUTS)and clinical factors in patients with benign prostatic hyperplasia (BPH).Methods 146 cases of BPH patients were taken as the research object.Age,duration of disease,prostate volume,prostate specific antigen(PSA),prostate hyperplasia,emotion,serum estrogen and so on were compared and analysed by retrospective investigation method.In patients with LUTS as the dependent variable,in order to lead to the patients with LUTS of all kinds of factors as independent variables,medical records were compared with Logistic regression anaysis after single factor analysis.Results Age,maximum urinary flow,HAMD,PSA score and serum estrogen were important factors (P 〈 0.05).Logistic regression analysis showed that age,maximum urine flow,PSA and serum estrogen were independent risk factors (P 〈 0.05).Conclusions Age increasing,maximum urine flow rate (〈 5mL/s),PSA and serum estrogen level are important risk factors for the severity of LUTS associated with BPH.
出处 《国际泌尿系统杂志》 2016年第3期353-356,共4页 International Journal of Urology and Nephrology
基金 2014年深圳市福田区卫生公益性科研项目(F1WS2014009)
关键词 前列腺增生 危险因素 Prostatic Hyperplasia Risk Factors
  • 相关文献

参考文献13

二级参考文献100

  • 1高瞻,伦立军,邵魁卿,沈建武,李奇,张军跃.前列欣胶囊联合盐酸坦洛新缓释胶囊治疗湿热瘀阻型前列腺增生疗效观察[J].湖南中医药大学学报,2011,31(10):17-20. 被引量:8
  • 2梁飞宇,屈晓冰,赵晓昆.炎症与良性前列腺增生症[J].国外医学(老年医学分册),2005,26(5):193-196. 被引量:4
  • 3Matsuda T, Fujime M, Suda K. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia [ J ]. Anal Quant Cytol Histol, 2006 ;28 (3) : 121-4.
  • 4Bravi F, Bosetti C, DalMaso L, et al. Food groups and risk of benign prostatic hyperplasia[J].Urology ,2006 ;67 ( 1 ) :73-9.
  • 5Marks LS, Roehrbom CG, Wolford E, et al. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone Index in predicting treatment response [ J]. J Urol,2007 ; 177(4) :1408-13.
  • 6Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guide- lines on assessment, therapy and follow-up of men with lower uri- nary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol, 2004, 46(5) : 547-554.
  • 7Robertson C, Link CL, Onel E, et al. The impact of lower uri- nary tract symptoms and comorbidities on quality of life: The BACH and UREPIK studies. BJU Int, 2007, 99(2) : 347-354.
  • 8Saigal CS, Joyce G. Economic costs of benign prostatic hyperpla- sia in the private sector. ] Urol, 2005, 173(4) : 1309-1313.
  • 9Zhou Q, Liao JK. Statins and cardiovascular diseases : From cho- lesterol lowering to pleiotropy. Curr Pharm Des, 2009, 15 (5) : 467-478.
  • 10St Sauver JL, Jacobson DJ, McGree ME, et al. Protective associ- ation between nonsteroidal antiinflammatory drug use and mea- sures of benign prostatic hyperplasia. Am J Epidemiol, 2006, 164(8) : 760-768.

共引文献71

同被引文献50

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部